[PMC free article: PMC5565739] [PubMed: 28856106] [CrossRef] 188
doi:10.1016/j.ecresq.2020.01.004CrossRefGoogle Scholar Williams, K, Brignell, A, Randall, M, Silove, N, Hazell, P
L.LiuQ.et al
The gut isnt the only barrier that can become permeable, or leaky
Compared with lixisenatide, exenatide twice daily, liraglutide, albiglutide and dulaglutide, semaglutide is associated with highest nausea and vomiting rates, yet also with highest rates of improvement in glycemic control and weight loss (132)
"I don't think that anyone is anticipating we'll see any products being approved in January or February," Tadrous said in an interview on Monday, suggesting summer would be more likely